Prestige Consumer Healthcare (PBH) EBITDA Margin (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly EBITDA Margin came in at 29.1% in Q4 2025, down 257.0% year-on-year from 18.54% in Q4 2024, and little changed quarter-over-quarter from 29.06% in Q3 2025.
Prestige Consumer Healthcare (PBH) EBITDA Margin (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's EBITDA Margin history runs 16 years deep, the most recent figure standing at 29.1% for Q4 2025.
- On a quarterly basis, EBITDA Margin fell 257.0% year-over-year to 29.1% in Q4 2025; TTM through Dec 2025 was 29.21%, a 35.0% decrease from a year earlier, with the FY2025 full-year figure at 29.6%, down 83.0% from the prior year.
- EBITDA Margin was little changed at 29.1% in Q4 2025 per PBH's latest filing, from 29.06% in the prior quarter.
- Across five years, EBITDA Margin topped out at 33.93% in Q2 2021 and bottomed at 98.3% in Q1 2023.
- The 5-year median for EBITDA Margin is 29.77% (2024), against an average of 23.6%.
- Across the five-year window, EBITDA Margin sank 12730 bps in 2023 and soared 12795 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 30.09% in 2021, then climbed by 5 bps to 31.64% in 2022, then fell by 3 bps to 30.71% in 2023, then gained by 3 bps to 31.68% in 2024, then slipped by 8 bps to 29.1% in 2025.
- Per Business Quant, the three latest PBH EBITDA Margin figures stand at 29.1% (Q4 2025), 29.06% (Q3 2025), and 28.76% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 29.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.10% |
| Sep 30, 2025 | 29.06% |
| Jun 30, 2025 | 28.76% |
| Mar 31, 2025 | 29.82% |
| Dec 31, 2024 | 31.68% |
| Sep 30, 2024 | 29.72% |
| Jun 30, 2024 | 26.97% |
| Mar 31, 2024 | 29.66% |
| Dec 31, 2023 | 30.71% |
| Sep 30, 2023 | 30.82% |
| Jun 30, 2023 | 30.50% |
| Mar 31, 2023 | -98.30% |
| Dec 31, 2022 | 31.64% |
| Sep 30, 2022 | 29.17% |
| Jun 30, 2022 | 31.41% |
| Mar 31, 2022 | 29.01% |
| Dec 31, 2021 | 30.09% |
| Sep 30, 2021 | 28.44% |
| Jun 30, 2021 | 33.93% |
| Mar 31, 2021 | 29.84% |